Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of nasopharyngeal squamous carcinoma~* EBV-LMP1 positive~* Signed Informed Consent Form~Exclusion Criteria:~* Abnormal laboratory results within 45 days prior to study entry~* Participation in any study involving an experimental drug or an experimental medical device in 30 days prior to study entry~* Current pregnancy~* Inability to provide informed consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DZ1 (Type: EXPERIMENTAL): DZ1 group receives DZ1 intratumoral injection in combination with radiation therapy.
- Saline (Type: PLACEBO_COMPARATOR): Placebo group receives saline injection in combination with radiation therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).